Abstract: Disclosed are methods of treating a chemotherapy-resistant cancer, of treating a cholangiocarcinoma, of treating a metastatic carcinoma, and of treating a transition cell urothelial carcinoma by administering a therapeutically effective amount of an endothelin B (ETB) receptor agonist and a chemotherapeutic agent to a subject afflicted with such a cancer.
Abstract: A method for treating cancer. The method including administering to a subject in need thereof, a combination including an effective amount of polymyxin B in combination with an effective amount of ATP, wherein the combination is effective in treating a tumor or cancer in the subject.
Abstract: Provided are peptides that can inhibit collagen synthesis, processing and/or secretion from scar forming cells or fibroblasts. Also provided are methods for using the peptides to produce an anti-fibrotic, anti-scarring, anti-inflammatory, and/or pro-regenerative effect, e.g., on an injured or diseased tissue.
Type:
Application
Filed:
April 22, 2016
Publication date:
October 6, 2016
Applicants:
MUSC FOUNDATION FOR RESEARCH DEVELOPMENT, UNIVERSITY OF SOUTH CAROLINA
Inventors:
Robert G. GOURDIE, Edie C. GOLDSMITH, L. Jane JOURDAN, Joshua Matthew RHETT, Michael J. YOST
Abstract: In some aspects, the invention teaches pharmaceutical compositions that include a TGF-beta ligand trap, and methods of using a TGF-beta ligand trap to treat, prevent, or reduce the progression rate of pulmonary hypertension (PH). The invention also provides methods of using a TGF-beta ligand trap to treat, prevent, or reduce the progression rate of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, right ventricular hypertrophy, diseases associated with excessive TGF-beta signaling, diseases associated with excessive GDF15 signaling, and diseases associated with excessive PAI-1 signaling. The invention further provides methods of using a TGF-beta ligand trap to reduce right ventricular systolic pressure in a subject.
Type:
Application
Filed:
November 21, 2014
Publication date:
October 6, 2016
Applicants:
THE BRIGHAM AND WOMEN'S HOSPITAL, INC., ACCELERON PHARMA INC.
Inventors:
Paul YU, Asya GRINBERG, Dianne S. SAKO, Roselyne CASTONGUAY, Rita STEEVES, Ravindra KUMAR
Abstract: The present invention provides a dendritic cell modulatory molecule which modulates, and preferable inhibits, the differentiation and maturation of mammalian dendritic cells. The invention also provides pharmaceutical compositions comprising the dendritic cell modulatory molecule and homologues and active fragments thereof, antibodies thereto and methods of treatment and screening methods which utilise such molecules.
Abstract: The disclosure relates to methods and compositions for rejuvenating neuromuscular junctions, and treating, preventing, or delaying the onset of, neuromuscular junction fragmentation and related disorders, neuromuscular junction degeneration and related disorders, motor neuron degeneration and related disorders, skeletal muscle conditions (e.g., muscle atrophy), and neuromuscular diseases (e.g., amyotrophic lateral sclerosis).
Abstract: A microneedle device for delivering therapeutic ingredients to the dermis or epidermis. The device contains biodegradable microneedles, which extend from a backing, and are sandwiched between a cap film and a film which is coextensive with the tips of the microneedles and the spaces on the backing between the microneedles.
Abstract: Provided is an agent for the treatment of an autoimmune disease, the agent comprising CTRP3, and a method for the treatment of an autoimmune disease, the method comprising: administering an agent, which comprises CTRP3 for the treatment of an autoimmune disease, to a subject in need of a treatment of an autoimmune disease.
Abstract: The present invention provides methods and compositions for the use of IL-22 for treating conditions of intestinal injury and inflammatory conditions such as graft vs. host disease. Specifically, IL-22 can be used to increase Intestinal Stem Cell (ISC) recovery and for enhancing immune reconstitution following allogeneic hematopoietic transplantation. In particularly preferred embodiments, the present invention provides methods of using therapeutic IL-22, including a dimeric form of IL-22, in therapeutic compositions for treating graft vs. host disease, including hepatic, thymic, gastrointestinal, or other graft vs. host disease in hematopoietic stem cell transplant patients and in patients with inflammatory intestinal conditions.
Type:
Application
Filed:
November 7, 2014
Publication date:
October 6, 2016
Inventors:
Marcel VAN DEN BRINK, Alan HANASH, Caroline LINDEMANS, Tom TANG
Abstract: The present disclosure relates to methods for treating human subjects afflicted with chronic heart failure. The methods described herein employ administration of relaxin.
Type:
Application
Filed:
April 25, 2016
Publication date:
October 6, 2016
Inventors:
Elaine Unemori, Sam Teichman, Thomas Dschietzig, Dennis R. Stewart, Martha Jo Whitehouse
Abstract: A composition comprising a peptide agent comprising amino acid sequence LKKTET (SEQ. ID NO.: 1) or Thymosin ?4 (T?4) can treat a corneal epithelial wound caused by epithelial debridement.
Abstract: A pharmaceutical combination for use in glycemic control in a type 2 diabetes mellitus patient, said combination comprising (i) lixisenatide or/and a pharmaceutically acceptable salt thereof, (ii) insulin glargine or/and a pharmaceutically acceptable salt thereof, and (iii) optionally metformin or/and a pharmaceutically acceptable salt thereof.
Type:
Application
Filed:
March 11, 2016
Publication date:
October 6, 2016
Inventors:
Christine Roy, Elisabeth Souhami, Nacima Demil, Jenny Ye
Abstract: The present invention provides a method of treatment for cancer in a subject comprising the administration of a prodrug, wherein the subject is colonised with an obligate anaerobic microorganism capable of expressing a polypeptide having nitroreductase activity, wherein the polypeptide exhibits preferential reduction of CB1954 to a 4-hydroxylamine (4HX) derivative instead of a 2-hydroxylamine derivative; and is capable of reducing CB1954 to the 4HX derivative with a Km of less than 30 micromolar. The present invention further provides an isolated polypeptide, nucleic acids encoding said polypeptide, vectors and host cells comprising said nucleic acids and vectors and uses of the above in treating solid tumours.
Abstract: This document provides methods and materials related to treating glaucoma, ocular hypertension, cardiovascular diseases, and renal diseases. For example, this document provides isolated nucleic acid molecules and viral vectors (e.g., lentiviral vectors) containing isolated nucleic acid molecules. Methods for reducing intraocular pressure as well as symptoms and progression of cardiovascular and renal diseases also are provided.
Abstract: An isolated polypeptide is disclosed comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 2773-5544 and 11089-11094, wherein the polypeptide has antimicrobial activity. Uses thereof for treating microbial infections are also disclosed.
Abstract: The invention provides methods and compositions that remove target genetic material from a subject by hydrodynamic delivery of an enzyme that degrades the target genetic material. The methods include delivering a solution include a nucleic acid, protein, or ribonucleoprotein to a blood vessel at a pressure sufficient to cause the material to enter cells proximal to the blood vessel. The enzyme may be Cas9 and may be provided with a guide RNA. The target genetic material may be viral genome with the guide RNA complementary to a portion of the viral genome.
Abstract: Provided herein are deglycosylating enzymes that remove a broad range of N-glycans from N-glycosylated proteins. Further provided are methods of recombinantly producing and expressing the deglycosylating enzymes. The presently described deglycosylating enzymes can be used to produce free glycans for characterization, and for prebiotic and immunostimulatory uses. In addition, the presently described deglycosylating enzymes can be used to produce deglycosylated proteins for characterization, to improve digestion, and to reduce immunogenicity.
Type:
Application
Filed:
March 24, 2016
Publication date:
October 6, 2016
Inventors:
Daniel Garrido, J. Bruce German, Carlito B. Lebrilla, David A. Mills
Abstract: The present subject matter is directed to a method of manufacturing and purifying an intraveneous injection of prothrombin complex concentration (PCC) from plasma Fraction III, comprising reconstituting a Fraction III paste in a buffer to create a Fraction III suspension; adjusting pH and temperature of the Fraction III suspension; performing PEG precipitation; centrifuging the Fraction III suspension and collecting a supernatant; filtering the supernatant; performing solvent detergent virus inactivation of the supernatant; undergoing weak anion exchange chromatography of the supernatant; twice washing and eluting two to three times; ultra-filtering the supernatant; adjusting pH of the supernatant; adjusting activity of a human factor IX of the supernatant; performing aseptic filtration and nano filtration for virus removal; and filling and lyophilizing to obtain the intraveneous injection of PCC.
Abstract: A therapeutic agent for the treatment of toxemia, preeclampsia and eclampsia and a method for preparing the therapeutic agent are disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or by other methods. Further, a method of using the presence of chymotrypsin in the maternal GI tract as a biomarker, to determine the likelihood of developing preeclampsia, a pregnancy induced hypertension, and eclampsia/toxemia is disclosed.
Abstract: The present invention provides therapies, vaccines, and predictive methods for Colony Collapse Disorder in bees and provides compounds for diagnosing, preventing, and treating Colony Collapse Disorder, A first non-limiting aspect of the present invention provides an isolated or synthesized peptide of up to 100 amino acid residues comprising at least one peptide sequence that is at least 70%, 80%, 90%, or 95% homologous with at least one Replikin peptide sequence identified in a CCD factor in honeybees or in any honeybee including but not limited to at least one Replikin sequence identified in at least one isolate of Varroa destructor, Nosema species, Deformed wing virus, Israeli acute paralysis virus, Kashmir bee virus. Sac brood virus, or in honeybees, including, but not limited to Apis mellifera and Apis cerana, or any Replikin sequence in the ATPase or complementary sex-determination (csd) gene of a honeybee.
Type:
Application
Filed:
November 21, 2014
Publication date:
October 6, 2016
Inventors:
Samuel BOGOCH, Elenore S. BOGOCH, Anne-Elenore Bogoch BORSANYI, Samuel Winston BOGOCH
Abstract: The present invention provides a method for restoring immune tolerance in vivo. The invention relates to the use of a recombinant gene encoding auto-antigens or parts thereof for restoring immune tolerance to the auto-antigens in vivo, under transcriptional control of polyomaviral early and late promoters. In a preferred embodiment, the invention relates to the use of recombinant polyomaviral gene delivery vector particles, such as simian virus 40 (SV40) viral vector particles encoding one or multiple auto-antigens or parts thereof under transcriptional control of the SV40 early and late promoter, for restoring immune tolerance to the auto-antigens in vivo. The invention also relates to compositions comprising recombinant genes or polyomaviral vectors and uses thereof as treatment for degenerative or dystrophic diseases.
Abstract: Myeloid derived suppressor cell (MDSC) inhibitory agents and vaccine and/or adjuvant enhancers are provided. Improved vaccine treatment regimens employing these agents are also provided. Cancer vaccines and methods for inhibiting tumor growth and cancer metastases are also presented. The myeloid derived suppressor cell (MDSC) inhibiting agents are described as bisphosphonates (such as liposomal clodronate) and CCR2 inhibitors and/or CCR2 antagonists. Methods for enhancing antibody titer levels in response to an antigen of interest are also provided.
Type:
Application
Filed:
March 17, 2016
Publication date:
October 6, 2016
Inventors:
Steven W. Dow, Angela J. Henderson, Leah Mitchell
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Type:
Application
Filed:
March 28, 2016
Publication date:
October 6, 2016
Inventors:
Andrea MAHR, Toni WEINSCHENK, Oliver SCHOOR, Jens FRITSCHE, Harpreet SINGH, Colette SONG
Abstract: The application is directed to in vitro-reared Plasmodium sporozoites of human host range wherein sporogony from gametocyte stage to sporozoite stage is external to mosquitoes, and methods of producing the same. Provided herein are in vitro-reared infectious Plasmodium sporozoites (SPZ) of human host range, particularly P. falciparum, P. vivax, P. ovale, P. malariae, and P. knowlesi, wherein sporogony from gametocyte stage to sporozoite stage is external to mosquitoes, and methods of producing the same.
Abstract: The invention provides active and passive immunization methods for preventing and treating Clostridium difficile infection, which involve percutaneous administration of C. difficile toxin-neutralizing polyclonal immune globulin, C. difficile toxoids, or combinations thereof. Also provided by the invention are C. difficile toxoids, C. difficile toxin-neutralizing polyclonal immune globulin, and methods of identifying subjects that produce C. difficile toxin-neutralizing polyclonal immune globulin.
Type:
Application
Filed:
January 4, 2016
Publication date:
October 6, 2016
Inventors:
William D. THOMAS, JR., Paul J. GIANNASCA, Zhenxi ZHANG, Wende LEI, Thomas P. MONATH
Abstract: The present invention pertains to a vaccine for administration to the upper respiratory tract of a ruminant to protect said ruminant against pneumonia caused by Mannheimia haemolytica, the vaccine comprising in combination live attenuated Mannheimia haemolytica bacteria, live attenuated parainfluenza-3 virus and live attenuated bovine respiratory syncytial virus, wherein the vaccine is for administration to the upper respiratory tract of the ruminant via intranasal atomisation of the vaccine.
Abstract: This invention provides kits, devices, and methods for the detection of antibodies that recognize one or more proteins and/or antigens from porcine reproductive and respiratory syndrome virus (PRRSV). The antibodies may be in a biological fluid of a PRRSV infected or at risk subject. The invention may be advantageously applied to both the diagnosis and prevention of PRRSV infection.
Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.
Abstract: The present application discloses methods for removing residual impurities from protein preparations. Such methods include addition of an anionic detergent to a solution comprising proteins of interest and cellular contaminants under non-precipitating conditions and passing the solution through an ion exchange column.
Type:
Application
Filed:
November 6, 2014
Publication date:
October 6, 2016
Inventors:
Carnley NORMAN, Eric SUDA, Kayla DOWLESS, Ruiz ASTIGARRAGA, Patrick BASTEK, Vaishali YANNONE
Abstract: The invention is directed to immunogenic compositions and methods for inducing an immune response against Piscine reoviruses in an animal. In another aspect, the invention relates to antibodies that bind Piscine reovirus polypeptides. In yet another aspect, the invention relates to methods for preventing, or reducing PRV infection in an animal.
Type:
Application
Filed:
June 14, 2016
Publication date:
October 6, 2016
Inventors:
W. Ian Lipkin, Gustavo Palacios, Ruth Toril Kongtorp, Edgar Brun
Abstract: The present disclosure concerns an oncolytic virus for the treatment of cancer, such as in brain cancer, for example glioblastoma. The oncolytic virus may exhibit reduced levels of neurotoxicity. The oncolytic virus may be an isolated viral particle capable of producing a cDNA polynucleotide that includes a sequence according to SEQ ID NO: 1 when the virus is in a host cell. The oncolytic virus may be an isolated viral particle that includes an RNA polynuclotide that includes a sequence according to SEQ ID NO: 2. The oncolytic virus may be an isolated viral particle having a genome that includes open reading frames that encode: proteins having sequences comprising SEQ ID NOs: 3, 4, 5, 6 and 7; or variants thereof.
Abstract: The invention relates to pan pollen immunogens such as polypeptides, proteins and peptides, and methods and uses of such immunogens for modulating or relieving an immune response in a subject. For example, the immunogens can be used for treating a subject for an allergic immune response or inducing or promoting immunological tolerance to the immunogen or a pollen allergen in a subject.
Type:
Application
Filed:
November 20, 2014
Publication date:
October 6, 2016
Applicants:
La Jolla Institute For Allergy And Immunology, ALK-Abelló A/S
Inventors:
Bjoern Peters, Alessandro Sette, Jason Greenbaum, Ilka Hoof, Lars Harder Christensen
Abstract: The present invention aims at providing an injectable vaccine composition that is safe, useful as a prophylactic or therapeutic agent for cancers or infectious diseases, and capable of inducing the systemic immune response safely and effectively.
Abstract: Disclosed is the use of fluorinated cyclic dinucleotides and pharmaceutically acceptable salts thereof as an adjuvant for the preparation of an oral vaccine. Further disclosed is the use of fluorinated cyclic dinucleotides and pharmaceutically acceptable salts thereof for enhancing the immune response to an orally administered vaccine.
Type:
Application
Filed:
November 18, 2014
Publication date:
October 6, 2016
Applicants:
BROCK UNIVERSITY, NATIONAL RESEARCH COUNCIL CANADA
Inventors:
Hongbin YAN, Wangxue CHEN, Rhonda KUO LEE
Abstract: Provided herein are combination therapies for the treatment of cancer. In particular, the disclosed methods are directed to treatment of cancer in a patient comprising administering an antibody that blocks the interaction between PD-1 and PD-L1 and an FGFR inhibitor, wherein the antibody that blocks the interaction between PD-1 and PD-L1 and the FGFR inhibitor are administered if one or more FGFR variants are present in a biological sample from the patient.
Type:
Application
Filed:
March 24, 2016
Publication date:
October 6, 2016
Inventors:
Jayaprakash KARKERA, Suso Jesus Platero, Raluca Verona, Matthew V. Lorenzi
Abstract: Embodiments of the present technology may include a composition for reducing microorganisms in the anterior nares or at other body sites. The composition may include a photosensitizer and a substance that enhances the eliminating, destroying, killing, or inhibiting of microorganisms in the anterior nares.
Abstract: A method of improving immune-function in mammals using selected 3-HPA producing lactic acid bacteria with a medium chain triglyceride (MCT) oil.
Abstract: A topical dermatological/pharmaceutical composition is described that includes BPO wherein the composition is a wash composition with desirable tolerance, stability and foaming properties. The composition can include: a) benzoyl peroxide (BPO); b) at least one mild surfactant selected from anionic and/or non-ionic surfactant classes; c) zinc gluconate; d) dipotassium glycyrrhizate; and e) at least one gelling agent. The composition is preferably in the form of an aqueous gel or an aqueous-alcoholic gel. Also described, is the use of such a composition for the treatment of dermatological disorders, and in particular in the treatment of acne.
Abstract: A topical carrier consists of 99% by weight or more of phosphatidylcholine and volatile solvent selected from the group consisting of: ethanol and its combinations with C3-and/or C4-alcohol and/or volatile silicone oil. The carrier may additionally comprise up to 1% by weight of antioxidant, colorant, odorant, and/or preservative, and up to 2% by weight of denaturant. Also disclosed are pharmaceutical, cosmetic and disinfectant compositions consisting of the carrier and pharmaceutically active agent, cosmetically active agent and/or disinfectant agent.
Abstract: The present invention generally relates to compositions and methods for topical or transdermal delivery and treatment of wounds and/or promoting wound healing. In some cases, the composition may include nitric oxide and/or peptides such as thyrotropin-releasing hormone (TRH) and/or GnRH (gonadotropin-releasing hormone). The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other structures containing nitric oxide, peptides, or both. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin, e.g., wounded skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.
Abstract: The present invention relates to a drug carrier having L-DNA nanocage structure prepared by using L-DNA, the mirror form of natural DNA, as a backbone. The drug carrier of the present invention has very superior cellular uptake efficiency and serum stability, so that it can be applied to deliver various drugs into cells usefully.
Type:
Application
Filed:
October 15, 2014
Publication date:
October 6, 2016
Applicant:
Korea Institute of Science and Technology
Abstract: Solid composition comprising (a) an anionic surfactant in combination with a water-soluble and basic polymer, or (b) a cationic surfactant in combination with a water-soluble and acidic polymer, and (c) at least one poorly water-soluble pharmaceutically active ingredient, and solid or liquid dosage forms, especially tablets, coated tablets, capsules or suppositories or aqueous solutions comprising the solid composition. The surfactant/polymer system is soluble in water and solubilises the active ingredient so that good bioavailability with therapeutical quantities may be attained. Aqueous solutions are suitable for nasal, parenteral or ophthalmic treatments.
Abstract: A medical device for implantation into vessels or luminal structures within the body is provided, which stimulates positive blood vessel remodeling. The medical device, such as a stent and a synthetic graft, is coated with a pharmaceutical composition consisting of a controlled-release matrix and one or more pharmaceutical substances for direct delivery of drugs to surrounding tissues. The coating on the medical device further comprises a ligand such as a peptide, an antibody or a small molecule for capturing progenitor endothelial cells in the blood contacting surface of the device for restoring an endothelium at the site of injury. In particular, the drug-coated stents are for use, for example, in balloon angioplasty procedures for preventing or inhibiting restenosis.
Type:
Application
Filed:
November 20, 2006
Publication date:
October 6, 2016
Applicant:
OrbusNeich Medical, Inc.
Inventors:
Robert John Cottone, JR., Stephen M. Rowland, Sherry Parker
Abstract: Methods of preparing lyophilized preparations of Factor IX which preserve more than 90% of the calcium binding property of Factor IX are disclosed. Factor IX formulated with trehalose shows a superior stability profile after 12 weeks storage at 25° C./60% relative humidity (RH) and 40° C./75% RH relative to Factor IX formulated without trehalose. The data suggest that the inclusion of trehalose in the formulation could allow for temperature excursions or even long-term room temperature storage of a Factor IX lyophilized product. The formulations tested contained 10 mM histidine pH 6.8, 3% mannitol, 66 mM sodium chloride, 0.0075% Polysorbate 80, with and without 1% trehalose. Upon storage at 40° C./75% RH or 25° C./60% RH over 12 weeks the trehalose-containing formulation was comparable to product stored at 2-8° C. while the formulation without trehalose was found to undergo significant aggregation and loss of activity.